Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maria Diaz"'
Autor:
Matthew C. Coffey, Richard G. Vile, Timothy Kottke, Hardev Pandha, Alan Melcher, Jill Thompson, Kevin J. Harrington, Shane Zaidi, Kevin G. Shim, Christopher Parrish, Liz Ilett, Rosa Maria Diaz, Karishma Rajani
Publikováno v:
Molecular Therapy. 24:166-174
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor activity is directly associ
Autor:
Miran Blanchard, Kevin J. Harrington, Jill Thompson, Shane Zaidi, Richard G. Vile, Michael P. Grams, Rosa Maria Diaz, Kevin G. Shim, Kenneth R. Olivier, Keith M. Furutani, Hardev Pandha, Alan Melcher, Svetomir N. Markovic, Sean S. Park, Karishma Rajani
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 93:577-587
Purpose The oligometastatic state is an intermediate state between a malignancy that can be completely eradicated with conventional modalities and one in which a palliative approach is undertaken. Clinically, high rates of local tumor control are pos
Autor:
Alan Melcher, Richard G. Vile, Jill Thompson, Timothy Kottke, Rosa Maria Diaz, Timothy E. Peterson, Kevin G. Shim, Peter Selby, Karishma Rajani, Ian F. Parney, Elizabeth Ilett, Susan C Short, Shane Zaidi, Julia V. Cockle
Publikováno v:
Neuro-Oncology. 18:518-527
Background Systemic delivery of a complementary cDNA library expressed from the vesicular stomatitis virus (VSV) treats tumors by vaccinating against a wide range of tumor associated antigens (TAAs). For subcutaneous B16 melanomas, therapy was achiev
Autor:
Christine M. Pulido, Jill Thompson, Timothy Kottke, Rosa Maria Diaz, Feorillo Galivo, Alan Melcher, Phonphimon Wongthida, Diana Rommelfanger, Richard G. Vile, Karen M. Kaluza
Publikováno v:
Human Gene Therapy. 22:1343-1353
We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can
Autor:
Gerard J. Nuovo, Timothy Kottke, Kevin J. Harrington, Alan Melcher, Debabrata Mukhopadhyay, Peter Selby, Jill Thompson, Richard G. Vile, Jose S. Pulido, Matthew C. Coffey, Rosa Maria Diaz, Hardev Pandha, Elizabeth Ilett, John D. Chester
Publikováno v:
Molecular Therapy. 19(10):1802-1812
We have previously reported that a burst of vascular endothelial growth factor (VEGF) signaling to tumor-associated endothelium induces a proviral state, during which systemically delivered oncolytic reovirus can replicate in endothelium, thereby ind
Autor:
Alan Melcher, Feorillo Galivo, Jill Thompson, Kevin J. Harrington, Steven M. Albelda, Rosa Maria Diaz, Timothy Kottke, Phonphimon Wongthida, Candice Willmon, Richard G. Vile
Publikováno v:
Molecular Therapy. 19(1):140-149
Despite having potent oncolytic activity, in vitro, direct intratumoral injection of oncolytic vesicular stomatitis virus (VSV) into established AE17ova mesothelioma tumors in C57Bl/6 mice had no therapeutic effect. During studies to combine systemic
Autor:
Jian Qiao, Jay D. Naik, John C. Bell, Hongxun Wang, K.J. Harrington, Kelley Parato, Timothy Kottke, Richard G. Vile, Candice Willmon, Andrew W. Hudacek, Jill Thompson, Rosa Maria Diaz, Alan Melcher, John D. Chester, Peter Selby
Publikováno v:
Gene Therapy. 15:604-616
Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promi
Autor:
Timothy Kottke, Rosa Maria Diaz, Richard G. Vile, Kevin J. Harrington, Alan Melcher, Geoff Hall, Glen N. Barber, Dragan Jevremovic, Peter Selby, Feorillo Galivo, Jill Thompson, Phonphimon Wongthida, John D. Chester
There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9641f09bad1f86170663d3fe5ba0310
https://europepmc.org/articles/PMC2729455/
https://europepmc.org/articles/PMC2729455/
Autor:
Richard G. Vile, Hongxun Wang, Johann S. de Bono, Katie Twigger, Christine A. White, Jian Qiao, Timothy Kottke, Kevin J. Harrington, Jill Thompson, Hardev Pandha, Rosa Maria Diaz, Alan Melcher, Matthew C. Coffey, Peter Selby
Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fc9ce042a6dddc7c7e13286410184e
https://europepmc.org/articles/PMC3046731/
https://europepmc.org/articles/PMC3046731/